leadf
logo-loader
viewMedexus Pharmaceuticals Inc

Medexus Pharmaceuticals gets Health Canada approval to market Gleolan for neurosurgery

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) CEO Ken d’Entremont tells Proactive the group has received a notice of compliance from Health Canada, granting the company approval to market its tumor imaging agent Gleolan in the country.

d’Entremont says with Gleolan, which is essentially a dye that can make tumors and their small, finger-like projections more visible, the group can now able to access a much larger group of adult patients suffering from high-grade gliomas in Canada.

Quick facts: Medexus Pharmaceuticals Inc

Price: 4.29 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $62.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Medexus Pharmaceuticals 'becoming very much a US story' with 75% net revenue...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) CEO Ken d’Entremont tells Proactive he sees the group as 'becoming very much a US story.' d’Entremont says with 75% net revenue coming from the states, its important the firm makes its stock available to US investors, citing an increase in...

on 09/08/2020

2 min read